Subdermal Contraceptive Implants Market Share

  • Report ID: 5300
  • Published Date: Nov 25, 2025
  • Report Format: PDF, PPT

Subdermal Contraceptive Implants Market - Regional Analysis

North American Market Insights

Subdermal contraceptive implants market in North America is predicted to account for the largest share of 55% by 2035 impelled by the availability of contraceptive implants. Nexplanon which resembles a matchstick in size and is a tiny, thin rod is the implant that is offered in the US. Besides this, Canada has now authorized the use of Nexplanon to give patients in the country an essential and long-overdue expansion of their options for contraception. For instance, Women in the US had access to over 50% of the contraceptive products available globally, as compared to approximately 34% for Canadian women.

APAC Market Insights

The APAC subdermal contraceptive implants market is estimated to be the second largest, during the forecast timeframe led by rising government’s initiatives to improve access to contraceptive methods. The Indian government has made important strides towards enhancing sexual and reproductive health at the national, local, and rural levels by launching various initiatives such as Mission Parivar Vikas, which will greatly expand access to family planning and contraceptives. For instance, lately, India's adoption of the Sustainable Development Goals (SDG) indicator over 3 intends to ensure that everyone has access to sexual and reproductive health care services by 2030 by meeting three-fourths of family planning needs with contemporary contraceptive methods.

Subdermal Contraceptive Implants Market size

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of subdermal contraceptive implants is assessed at USD 1.15 billion.

The global subdermal contraceptive implants market size was valued at around USD 1.11 billion in 2025 and is projected to grow at a CAGR of more than 3.7%, reaching USD 1.6 billion revenue by 2035.

North America is predicted to hold the largest share of 55% by 2035, impelled by the widespread availability of contraceptive implants such as Nexplanon.

Key players in the market include Shanghai Dahua Pharmaceutical Co., Ltd, Bayer AG, Wyeth Pharmaceuticals, Baxter, Gerresheimer AG, Pfizer, Inc., Novartis AG, Schott AG, Eli Lilly and Company.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos